GlassScriptPhysician profile
Rachel Ek Slater
NPI 1558614370
$3,614.27
in general payments reported to CMS, 2019-2025
19 companies · $1,122 in 2025
The $1,122 reported for 2025 was more than what 92% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $101 · 2020: $118 · 2021: $166 · 2022: $648 · 2023: $352 · 2024: $1,107 · 2025: $1,122.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,581.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,580.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $835.91 | 2019-2025 | Rocklatan, Tryptyr, Rhopressa |
| Sun Pharmaceutical Industries INC. | $436.71 | 2020-2025 | Cequa |
| Abbvie INC. | $387.23 | 2023-2025 | |
| Bausch & Lomb Americas INC. | $345.92 | 2022-2025 | Miebo, Xiidra, Infuse |
| Dompe US, INC. | $324.79 | 2024-2025 | Oxervate |
| Genentech USA, INC. | $301.79 | 2022-2024 | Vabysmo |
| Amgen INC. | $248.67 | 2024-2025 | Tepezza |
| Tarsus Pharmaceuticals, INC. | $154.73 | 2025 | Xdemvy |
| Aerie Pharmaceuticals, INC. | $108.98 | 2020-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $104.56 | 2019-2021 | |
| Oyster Point Pharma, INC. | $90.41 | 2022-2024 | Tyrvaya |
| Mallinckrodt Hospital Products INC. | $55.19 | 2025 | Acthar |
| Allergan, INC. | $54.41 | 2020-2022 | |
| Astellas Pharma US INC | $41.72 | 2024 | Izervay |
| Horizon Therapeutics Plc | $40.87 | 2023 | Tepezza |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lkc Technologies, INC. | $28.82 | 2025 | |
| Johnson & Johnson Surgical Vision, INC. | $25.34 | 2019 | |
| Novartis Pharmaceuticals Corporation | $15.84 | 2022 | |
| Shire North American Group INC | $12.38 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachel Slater listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.